Sensus Healthcare (SRTS) Stock: Buy, Sell, or Hold?
SRTS - Sensus Healthcare, Inc
$2.95
-0.04 (-1.34%)
▼
5d:
+1.37%
30d:
-11.41%
90d:
-3.91%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When SRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SRTS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SRTS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SRTS is currently trading at $2.95, which is considered oversold relative to its 30-day fair value range of $3.00 to $3.34. From a valuation perspective, the stock is trading at a discount (Forward PE: -17.0) compared to its historical average (204.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRTS is showing sideways momentum. The price is currently testing key support at $2.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SRTS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.38 (+82.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SRTS is showing sideways momentum. The price is currently testing key support at $2.91. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SRTS scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.38 (+82.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.00 -
$3.34
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
Protect Your Profits
Holding SRTS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.2% below Wall St target ($5.38)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.00 -
$3.34
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.91
Resistance Level
$3.14
Current Trend
Sideways
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-17.02
Wall Street Target
$5.38
(+82.2%)
Revenue Growth (YoY)
-68.7%
Earnings Growth (YoY)
433.3%
Profit Margin
-88.4%
PE vs Historical
-17.0 vs 204.1
CHEAP
Share & Embed Analysis
Last updated: October 02, 2026 4:21 AM ET
Data refreshes hourly during market hours. Next update: 5:21 AM
Data refreshes hourly during market hours. Next update: 5:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 64 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 48 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 57 HOLD |
Advanced SRTS Option Strategies
Professional options setups generated by AI based on today's SRTS price and gamma walls.
